Patients with arterial hypertension and obesity: targeting biomarkers as a personalised therapeutic approach

Abstract

This literature review focuses on the treatment of patients with arterial hypertension (AH) and obesity, from the point of view of personalised medicine (PM). One of the PM approaches is the use of biochemical markers which reflect normal and pathologic processes in the human body, as well as the presence of a disease or the response to a treatment. In patients with AH and obesity, antihypertensive medications should also affect the levels of biomarkers. This requirement is met by perindopril, an angiotensin-converting enzyme (ACE) inhibitor with high tissue specificity. Pathogenetic therapy with perindopril provides an opportunity to target the biomarkers of adipokine activity, endothelial dysfunction, inflammation, and other processes.

Keywords

• arterial hypertension
• antihypertensive treatment
• obesity
• personalised medicine
• biomarkers
• leptin, adiponectin
• endothelial dysfunction
• inflammation markers
• insulin resistance
• angiotensin-converting enzyme inhibitor
• perindopril
• prestarium a